proximately 20% of the manuscripts submitted for publication.
In the last six years Diabetologia has changed its appearance by structuring its abstracts and using subheadings in the table of contents. Its new cover was designed to signal the journal's interdisciplinary character in both basic and clinical science [1] . The ratio between these two major aspects of research, which is always a matter of debate [2] , ranges about 1.0.
Major improvements in the handling of Diabetologia will result from the set-up of a centralised copy-editing unit at the EASD headquarters in Düsseldorf, as of October 2003, which will report to the Editor-in-Chief, wherever he may reside in Europe. This change will reduce the administrative burden of the Editorial Office and avoid any momentary loss of technical expertise when a new editor is appointed and the Editorial Office is moved to another European location.
To attract even more high quality scientific reports Diabetologia has recently established two Annual Best Paper Awards of € 4000 each for excellence in diabetes research in either basic or clinical science. Applicants should preferably be younger than 40 years of age and apply with the submission of their manuscript and approval of their senior author. The final selection is jointly made by the Editor-inChief and the Deputy Editors based on the paper's evaluation by its respective referees and on the suggestions given by the Editorial Board members. At this year's Diabetes-Congress in Paris it was a great pleasure to give the first Annual Best Paper Awards to Dr. M. Trento [3] from Italy (clinical science) and to Dr. M. Shibasaki [4] from Japan (basic science).
Considering the contents of the papers published in Diabetologia in the last 6 years, the major concern is not the methodological quality of the reports accepted or the balance between clinical and basic science articles, it is the overemphasis on predictable research. There are only few studies covering uncharted territories or critically evaluating common-treatment regimens as to their long-term clinical benefit for the diabetic patient. This phenomenon not only applies to reports submitted to Diabetologia, but are also seen in other journals of all sorts.
There is no doubt that changes in metabolic detail-including substrates, regulatory hormone release and signalling processes as well as their interdependence-are an investigator's bonanza particularly in doing research on states of insulin deficiency. Such studies can be planned and completed within a reasonable time and can help establish an academic career. But there is also no doubt that although such studies frequently foster our understanding of the pathophysiology of a given disease, they do not necessarily improve patient care.
A bonanza, which is still largely untapped, is the neglected but clinically important identification of treatment algorithms useful for diabetes care and diabetes prevention. Such studies require a critical mind with regard to clinical science and are difficult to carry out as they potentially interfere with cherished traditional treatment schedules which are frequently not strictly defined. Intensified insulin therapy would be a good example for such clinical research as the algorithms used for this highly promoted form of insulin treatment are of utmost diversity, frequently undefined and not described, even in reports of extreme importance [5] .
Having said this I have to admit that I have greatly enjoyed the privilege of reading diabetes research at its best, first hand and even before it goes into print. The educational benefit of this exercise is remarkable, similar to that of giving rounds, where one is also subject to continuous medical education by younger colleagues asking questions which occasionally are difficult to answer. In the case of the position of Editor-inChief this potentially difficult situation can, however, be easily overcome by asking for an additional expert review from either a member of the Editorial Board or a specialist referee. Regretfully, these editorial safeguards do not always work, that is when unhappy authors, whose manuscripts have been rejected, knock at the door with e-mails, faxes and telephone calls. In this moment of truth, the Editor-in-Chief is alone. This can be an interesting experience. However, before things become too serious, the situation can be overcome by offering a 'New Submission' of a thoroughly revised and amended research report, which then again has a 20% chance of being accepted-a lesson I learned a long time ago from the legendary Dr. Ingelfinger.
Besides such anecdotes there will be more serious challenges for scientific journals in the future. These will include among others more correct definitions of authorship, disclosure of financial conflicts of interest, electronic publishing and competition with open-access journals, which just have gained support from major private funding organisations [6] . These and other developments will have to be handled by the incoming Editor-in-Chief, Dr. Edwin Gale from Bristol, who not only is an excellent clinical scientist but also a medical journalist of high calibre. He will, from now on, take full responsibility for Diabetologia. My best wishes go to him, the incoming editorial team and to Diabetologia for the years to come.
Werner K. Waldhäusl, Editor-in-Chief Vienna, December 2003
